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Intracellular inclusions of the TAR-DNA binding protein 43 (TDP-43) have been reported in amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Raremutations in TARDBP have been linked to both ALS
and FTD-TDP suggesting that TDP-43 dysfunction is mechanistic in causing disease. TDP-43 is a predominantly
nuclear protein with roles in regulating RNA transcription, splicing, stability and transport. In ALS, TDP-43 aber-
rantly accumulates in the cytoplasm of motor neurons where it forms aggregates. However it has until recently
been unclearwhether the toxic effects of TDP-43 involve recruitment tomotor axons, andwhat effects thismight
have on axonal growth and integrity. Here we use chick embryonic motor neurons, in vivo and in vitro, to model
the acute effects of TDP-43.We show that wild-type and two TDP-43mutant proteins cause toxicity in chick em-
bryonic motor neurons in vivo. Moreover, TDP-43 is increasingly mislocalised to axons over time in vivo, axon
growth to peripheral targets is truncated, and expression of neuroﬁlament-associated antigen is reduced relative
to control motor neurons. In primary spinal motor neurons in vitro, a progressive translocation of TDP-43 to the
cytoplasm occurs over time, similar to that observed in vivo. This coincides with the appearance of cytoplasmic
aggregates, a reduction in the axonal length, and cellular toxicity,whichwasmost striking for neurons expressing
TDP-43 mutant forms. These observations suggest that the capacity of spinal motor neurons to produce and
maintain an axon is compromised by dysregulation of TDP-43 and that the disruption of cytoskeletal integrity
may play a role in the pathogenesis of ALS and FTD-TDP.
© 2014 The Authors. Published by Elsevier Inc.
Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset, relentlessly pro-
gressive neurodegenerative disease. TDP-43 is the major protein
present in neuronal and glial inclusions in both sporadic and familial
forms of ALS and tau-negative frontotemporal dementia (FTD-TDP),
(Forman et al., 2007; Mackenzie et al., 2007; Neumann et al., 2006).
We, and others, have shown that mutations in the C terminal domain
of the gene encoding TDP-43 (TARDBP) are causally linked to familial
and sporadic ALS and FTD-TDP (Blair et al., 2010; Chio et al., 2009;
Corrado et al., 2010; Damme et al., 2010; Drepper et al., 2011; Gitcho
et al., 2008; Kabashi et al., 2008; Kwiatkowski et al., 2009; Rutherford
et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Vance
et al., 2009; Yokoseki et al., 2008). Intriguingly, TDP inclusions are
also found in a smaller proportion of patients with Alzheimer's and
Parkinson's disease, but their role in the pathogenesis is uncertain
(Nakashima-Yasuda et al., 2007).
TDP-43 is a predominantly nuclear protein with DNA and RNA bind-
ing properties. It hasmultiple roles in RNA-processing that are crucial in
early development, as genetic deletion of TDP-43 is embryonic lethal
between embryonic days 3 and 8 (Chiang et al., 2010; Kraemer et al.,
2010; Sephton et al., 2010; Wu et al., 2010). TDP-43 can act as a tran-
scriptional repressor and is implicated in exon skipping/retention,
RNA transport and stability and micro RNA biogenesis (Casafont et al.,
2009; Strong et al., 2007). In ALS and FTD-TDP, prominent TDP-43 ag-
gregates are present in the cytoplasm of surviving neurons, which
often show clearing of the protein from the nucleus (Neumann et al.,
2006; Vance et al., 2009). However, it remains unclear whether the
gain or loss of TDP-43 function is mechanistic in disease. In cellular
and some animal models overexpressing TDP-43, deletion of the RNA
binding and C terminal domains was required for toxicity rather than
cytoplasmic mislocalisation (Voigt et al., 2010; Wegorzewska et al.,
2009). It is possible that both the loss of nuclear TDP-43 and its seques-
tration in the cytoplasm lead to defective RNA processing (Lagier-
Tourenne et al., 2009; Strong MJ, 2010). The extent to which TDP-43 is
localised in axons has been uncertain, but a recent study shows its re-
cruitment to motor axons, where it co-localises with a number of
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mRNA-binding proteins (Fallini et al., 2012). Given that TDP-43 binds to
nearly one third of all neuronal RNA transcripts, its effects could impact
a very wide array of cellular pathways, many of which are critical in
neuronal development including components of the cytoskeleton
(Polymenidou et al., 2011; Tollervey et al., 2011a, 2011b). For example,
TDP-43 interacts directly with the 3′ UTR of the low molecular weight
(68 kDa) neuroﬁlament mRNA (NFL) (Strong et al., 2007), stabilising
it and preventing its degradation. Conversely, in ALS the expression of
the NFL mRNA is suppressed and it is preferentially sequestered to
stress granules (Strong et al., 2007; Volkening et al., 2009).
We have previously shown that in vivo over-expression of TDP-43
mutant forms in the chick spinal cord analysed over short time intervals
(24 h) leads to cell death and developmental delay (Sreedharan et al.,
2008). Here we investigate the effects of TDP-43 mutant and wild-
type forms on motor neuron integrity and axon outgrowth in vitro and
in vivo over a longer period of time, using the chick embryo model.
In vivo, we found that spinal motor neurons over-expressing TDP-43
(wild-type and mutant) showed a progressive increase in cytoplasmic
and axonal TDP-43mislocalisation over time. Those neurons expressing
mutant TDP-43 were more likely to display prominent nuclear aggre-
gates. A down-regulation of neuroﬁlament-associated antigen (NAA)
was observed in axons expressing mutant TDP-43, accompanied by
de-fasciculation and truncation of the axon projections. When the
same constructswere expressed in dissociated E6 spinalmotor neurons,
TDP-43 aggregation was observed along with a reduction in axon out-
growth. This was more prominent in cells expressing mutant forms
than in those expressing wild-type TDP-43. Taken together, our data
suggest that over-expression of TDP-43 (wild-type and mutant) leads
to cytoplasmic and axonal mislocalisation of TDP-43 in motor neurons,
and an impairment of axon growth.
Materials and methods
Plasmids
The N-terminal HA and C-terminal Myc constructs were cloned
as described previously (Sreedharan et al., 2008; all cloned into the
pCI-neo vector). For EGFP-tagged TDP-43 WT and mutant plasmids,
the cDNA insert was cloned into the pEFGP-C1 (N-terminal GFP) vector
at the XhoI and BamHI sites. Mutant forms of TDP-43 were those con-
taining either the M337V familial mutation, or the Q331K sporadic
mutation. Direct sequencing was used to conﬁrm clone alignment and
mutagenesis.
Embryos
Pathogen-free white Leghorn hens' eggs were incubated at 39 °C
and 70% humidity. Embryos were staged according to Hamburger and
Hamilton (1951) and electroporated at HH stage 14 (E2.5).
In ovo electroporation
In ovo electroporationwas used to over-express the genes of interest
in one half of the spinal cord. On the day of electroporation a small
window was cut into the shell to expose the embryo. PBS containing
1% Penicillin–Streptomycin (Invitrogen) was added to keep the embry-
os moist. Plasmid DNA constructs were dissolved in ddH2O to give a
ﬁnal concentration of 4.0 μg/μl. In all the experiments, pEGFPC1 expres-
sion vector was used to over-express EGFP as a control. Visualisation of
DNA during injectionwas aided by adding 0.5 μl of 10 mg/ml fast green
to 10 μl of DNA solution. A modiﬁed method of Momose et al. (1999)
was used, as previously described (Sreedharan et al., 2008). Eggs were
reincubated for 24–96 h, after which surviving embryos were dissected
and ﬁxed using 4% paraformaldehyde for 1–2 h at room temperature.
Cryosections
Fixed embryos were washed with PBST (PBS (Invitrogen) + 0.1%
Triton X-100 (Sigma)) 3 times for 30 min each at room temperature
and processed through ascending concentrations of sucrose (Sigma)
(10%, 20%, 30%) for 30 min each at room temperature. Theywere ﬁnally
washed in 1:1 30% Sucrose:OCT and then in OCT (CellPath Ltd.) for
30 min each at room temperature. Embryos were then embedded in
OCT, ﬂash-frozen in iso-Pentane (Sigma) using liquid nitrogen and sec-
tioned using a cryostat (Leica Microsystems) maintaining a thickness of
20 μm.
Immunoﬂuorescence
Frozen sections or cells (adhered to glass cover slips) were washed
in PBS, permeabilised using 0.5% and 0.05% PBST, respectively (1×
PBS + 0.5% Triton X-100). Sections or cells were then blocked using
10% FCS/PBS for 1 h and incubated with primary antibodies overnight
at 4 °C (rabbit anti-HA, 1:1000, Sigma; mouse anti-myc, 1:1000, NEB;
mouse anti-islet1/2 (4D5), 1:200, DSHB; mouse anti-neuroﬁlament
associated protein (3A10), 1:200, DSHB; chicken anti-GFP, 1:1000,
Abcam). Sections or cells were washed again with PBS, 3 times for
5 min each, before incubation with ﬂuorescent secondary antibodies
for 1–2 h at room temperature (anti-rabbit Alexa Fluor 488; anti-
mouse Alexa Fluor 568; anti-mouse Alexa Fluor 488, anti-chicken
Alexa Fluor 488, all 1:1000, all Invitrogen). After further washing,
sections or cells were mounted using Hardset Vectashield with DAPI
(Vector Laboratories). Images were captured using an Axiovert 4.0
(Carl Zeiss)microscopewith Image-Pro Express 6.0 (Media Cybernetics).
Adobe Photoshop 7.0 (Adobe Systems, Inc.) was used to process the
images.
Tunel
Apoptotic cell death was visualized on frozen sections according to
the manufacturer's protocol by nuclear DNA fragmentation analysis
using a DeadEnd Colorimetric TUNEL System (Promega Corporation,
USA). The number of apoptotic cells on the transfected and untrans-
fected sides of the embryo spinal cords was counted and the data
were inserted into GraphPad Prism to obtain the graphs. A total of
50–150 embryos were electroporated for each construct and the data
were analysed from 10 to 20 sections across at least 6 embryos from 3
sets of experiments.
Neurite length quantiﬁcation
ImageJ software was used for quantiﬁcation of neurite length. Cells
labelled with anti-GFP and anti-neuroﬁlament antibodies were imaged
using an Axiovert camera (Volocity software was used for image pro-
cessing) at 10× magniﬁcation. Images were then used to analyse the
total length of the neurites, length of longest and shortest neurites and
number of neurite branches using the NeuronJ plugin of ImageJ. A
total of ~150 cells per condition were analysed from 3 independent
experiments.
Spinal motor neuron cultures
Glass coverslips were coated with poly-D-ornithine and laminin
(15 μg/ml and 1 mg/ml, respectively; Sigma). Motor neuron cultures
were performed as previously described (Murray et al., 2010). For prep-
aration of spinal motor neurons, we used the ventral portion of the cer-
vical and thoracic spinal cord, which is enriched inmotor neurons at HH
stages 28–29 (E6). Dissociated neurons were plated on laminin-coated
coverslips, in Neurobasal medium containing 2% (v/v) B27 supplement,
2% (v/v) horse serum, 0.1% (v/v) β-mercaptoethanol, 0.35% (v/v)
Glutamax, 1% (v/v) penicillin/streptomycin (all from Gibco), 1% (v/v)
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chick embryo extract and 50 ng/ml CNTF (R&D Systems). Neuronswere
transfected with EGFP-WT, EGFP-Q, EGFP-M or pEGFP-C1 construct as a
control, using the chick nucleofection kit and an Amaxa machine
(Lonza). The efﬁcient transfection of these constructs was determined
by immunostaining using anti-GFP antibodies.
Rat cortical neuron cultures
Rat cortices were obtained at embryonic day 18. Upon dissection,
the cortical tissues were dissociated by digestion with Trypsin
(Worthington Biochemical) in Hanks buffer for 15 min and then trans-
ferred to Neurobasal medium (Gibco) with 2% B-27, 2% FBS, 1%
glutamax and 1% penicillin–streptomysin. The dissociated neurons
were then transfected with different plasmids (Control GFP and TDP-
43 wild-type and mutants) at a concentration of 2 μg or 4 μg of DNA
per 1 million cells using the Amaxa transfection kit and then plated at
a density of 140,000 cells in 35 mm confocal dishes (Thistle scientiﬁc)
for western blotting. The confocal dishes were previously coated with
poly-D-lysine and laminin (1 mg/ml, Sigma). The cells weremaintained
in Neurobasal medium supplemented with B-27, penicillin–
streptomysin and glutamax and incubated at 37 °C with 5% CO2. Cells
were then lysed and stored at−20 °C for western blotting.
Western blots
Proteins were separated by SDS-PAGE and transferred onto a
Hybond-P PVDF membrane (GE Healthcare) by wet transfer, incubated
with rabbit anti-TDP-43 antibody (10782-2-AP, Proteintech) or mouse
anti-GAPDH antibody (Sigma) followed by HRP-conjugated anti-rabbit
or anti-mouse secondary antibody (Dako). 43 kD and 70 kD bands
were detected using anti-TDP-43 antibody representing the endoge-
nous TDP-43 and exogenous EGFP-tagged TDP-43 respectively. In paral-
lel, the same samples were blotted using anti-GAPDH antibody. Blots
were developed using luminescent substrates (Roche). Bands were
quantiﬁed densitometrically using ImageJ software (National Institute
of Health) and standardised for each lane with respect to GAPDH.
Results
TDP-43 causes neurotoxicity in the chick embryo spinal cord
In order to gain insights into the effects of TDP-43wild-type andmu-
tant forms on motor axons in vivo, we electroporated constructs tagged
with N-terminal HA and C-terminal Myc into the chick spinal cord at
embryonic day 2.5 (E2.5). Mutant forms of TDP-43 were those contain-
ing either the M337V familial mutation, or the Q331K sporadic muta-
tion, which will be referred to as the M or Q mutant respectively. In
previous electroporation experiments in the chick spinal cord, we
have shown that transfection of 5–10% of cells in the chick embryo spi-
nal cord with Q and Mmutant constructs tagged with Myc/HA resulted
in a signiﬁcant increase in the number of apoptotic cells as compared to
wild-type TDP-43 transfection (Sreedharan et al., 2008). We have
further optimised the transfection conditions such thatwith higher con-
centrations of DNAwe obtain higher levels of transfection, up to 50–80%
cells in the chick embryo spinal cord; an EGFP plasmid was
electroporated as a control (Fig. 1A). Embryos were reincubated for
24 h until E3.5, cryo-sectioned and immunostained using anti-GFP anti-
bodies for the EGFP controls, orwith anti-Myc and anti-HA antibodies in
Fig. 1. Effects of over-expression of EGFP, HA/Myc-WT, HA/Myc-Q and HA/Myc-M TDP-43 isoforms in the chick embryo spinal cord. Representative transverse sections from embryos
electroporated with EGFP (A) or TDP-43 isoforms HA/Myc-WT (B), HA/Myc-Q (C) and HA/Myc-M (D). Panel Ai (green) labelled with anti-GFP; Panel Aii (blue) labelled with DAPI; Panel
Aiii (overlay yellowish) merge of Panels Ai and Aii; Panels Bi–Di, (green) labelled with anti-rabbit anti-HA; Panels Bii–Dii (red) labelled with anti-mouse anti-myc and Panels Biii–Diii
(DAPI (blue) with HA and MYC overlay (yellow/red)) show the merged images. Panels Aiv–Div show sections stained for apoptotic nuclei (TUNE-stained nuclei appear as black dots).
The spinal cords electroporated with EGFP (Aiv) or HA/Myc-WT (Biv) show very few TUNEL positive cells compared to embryos electroporated with HA/Myc-Q (Civ) and HA/Myc-M
(Div) which show frequent TUNEL-positive nuclei on the transfected side of the spinal cord. (E) Graph representing the average number of TUNEL +ve cells after electroporation of
EGFP, HA/Myc-WT, HA/Myc-Q and HA/Myc-M. A total of 122 embryos were electroporated for each construct and the data was analysed from 60 sections across at least 11 embryos
from 3 sets of experiments. The expression of Myc/HA was widespread in the spinal cord. Scale bar = 100 μm.
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order to determine the pattern of expression ofWT andmutant TDP-43
proteins (Figs. 1Ai-iii, Bi-iii, Ci-iii). To determine the number of cells
showing apoptosis, TUNEL DNA fragmentation analysis was used. Elec-
troporation of the EGFP control construct alone resulted in a small num-
ber of TUNEL +ve cells (Figs. 1Ai–iv). Electroporation of a TDP43 wild-
type construct (WT-TDP43) resulted in a slight increase in the number of
TUNEL +ve cells (Figs. 1; Bi–iv; E) but this was not signiﬁcantly differ-
ent from either the EGFP control (p N 0.05), or non-electroporated con-
trols (data not shown). Compared with the effects of both these
constructs, there was a signiﬁcant increase in the numbers of apoptotic
nuclei in spinal cords electroporated with TDP-43 Q or M mutant con-
structs (Figs. 1Ci–Div, E; p b 0.05 and 0.01 for Q and M vs EGFP respec-
tively). A qualititative comparison of these data showed increased levels
of toxicity of WT, Q and M forms relative to our previous study
(Sreedharan et al., 2008), inwhichwehad achieved a lower transfection
efﬁciency. Abnormal cleavage of TDP-43 produces phosphorylated
C-terminal fragments (CTF's) under pathological conditions. These
CTF's are enhanced within neuronal inclusions. Our strategy for
using N and C-terminal tagged TDP-43 constructs was to analyse
any difference in the localisation of the cleaved TDP-43 protein,
however, we did not see any apparent difference as the pattern of
HA and Myc staining was closely similar (Fig. 1).
We next electroporated EGFP-tagged TDP-43 WT and mutant forms
and compared their toxicity with EGFP controls. These EGFP-tagged
TDP-43 constructs produced an EGFP fusion protein in which the
GFP ﬂuorescence reproduces the TDP-43 expression pattern (Fig. 2).
We observed an increased number of neurons electroporated in the
spinal cord in vivo compared with previous studies (Fig. 2). Analysis by
TUNEL staining demonstrated a signiﬁcant increase in the number of
apoptotic nuclei in embryos electroporated with Q and M mutant
Fig. 2. Effects of over-expression of EGFP, EGFP-TDP-43WT, EGFP-TDP-43Q331K and EGFP-TDP-43M337V TDP-43 isoforms in chick embryo spinal cord. Representative transverse sections from
embryos electroporatedwith EGFP (A), or TDP-43 isoformsWT (B), Q (C) andM (D). Panels Ai–Di, EGFP ﬂuorescence (green); Panels Aii–Dii (DAPI (blue) with GFP overlay (green)) show
the unilateral expression of TDP-43 EGFP-tagged constructs in the spinal cord. Panel Aiii–Diii show the same sections stained for apoptotic nuclei (TUNEL-stained nuclei appear black). The
spinal cords electroporatedwithWT (Biii) show fewTUNEL-positive cells compared to embryos electroporatedwithQ (Ciii) andM (Diii)which show frequent TUNEL-positive nuclei on the
transfected side of the spinal cord. (E) Graph representing the average number of TUNEL +ve cells after electroporation of EGFP, and TDP-43 isoformsWT, Q andM. (F) Western blotsof
cortical neuron lysates using anti-TDP-43 antibodies representing endogenous levels of TDP-43 and over-expression of EGFP-tagged TDP-43 WT, Q and M as compared to GAPDH. Lanes
1, 2, 3, 4 represent EGFP, TDP-WT, TDP-QandTDP-Mat 2 µg, respectively, and lanes 5, 6, 7, 8 represent EGFP, TDP-WT, TDP-Q andTDP-Mat4 µg, respectively. (G) Semi-quantitative analysis
of endogenous TDP-43 protein expression levels in neuronal lysates.Western blotswere analysed using densitometry of the resulting 43 kD band. The levels of endogenous TDP-43 protein
expression increase for TDP-43-Q and TDP-43-M relative to EGFP-transfected cells for 4 μg of transfected DNA. (H) Semi-quantitative analysis of EGFP-tagged TDP-43 protein expression
levels in neuronal lysates.Westernblots using anti-TDP-43 antibodieswere analysedusing densitometry of the resulting 70 kD band. The levels of protein expression increasewith increas-
ing concentrations of transfectedDNA plasmid. A total of 25–50 embryoswere electroporated for each construct and the datawas analysed from60 sections across at least 11 embryos from
3 sets of experiments. Scale bar = 100 μm.
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constructs compared with those expressing EGFP (Figs. 2Ai–iii, Ci–Diii;
p b 0.01 for comparison with both M and Q mutants; Fig. 2E). There
was also a modest but signiﬁcant increase in the number of apoptotic
cells in embryos expressing WT-TDP-43 compared with EGFP controls
(Figs. 2Bi–Biii; p b 0.05; Fig. 2E). Comparison of the levels of EGFP-
tagged TDP-43 from transfections using low or high plasmid
Fig. 3. Cytoplasmicmis-localisation of mutant TDP-43. Representative images from embryos electroporatedwith EGFP (Ai–Aii), or TDP-43 isoformsWT (Bi–Bii),Q (Ci–Cii) andM (Di–Dii).
Panels Ai–Di, EGFP ﬂuorescence (green) show the expression of EGFP and TDP-43 EGFP-tagged constructs in the spinal cord; Panels Aii–Dii confocal images of individual cells. Over-
expression of mutant TDP-43 causes diffuse cytoplasmic localisation along with nuclear inclusions (arrows). (E) Graph representing the average percentage of cells showing a nuclear
vs cytoplasmic localisation after electroporation ofWT, Q andM. Asterisks denote signiﬁcance levels. Scale bar = 100 μm.
Fig. 4. Axonal mis-localisation of TDP-43 at E6.5 of embryonic development. Representative transverse sections from embryos electroporated with EGFP (Ai–Aiii), or TDP-43 isoforms
WT (Bi–Biii; n = 14), Q (Ci–Ciii; n = 12) and M (Di–Diii; n = 16). Panels Ai–Di show entire spinal cords demonstrating unilateral expression of EGFP-tagged constructs (green)
at E4.5; Panels Aii–Dii represent highermagniﬁcation of electroporated sides of the spinal cords of embryos in (Ai–Di), sections are stained for EGFP (green) and neuroﬁlament-associated
antigen (NAA; red). Panels Aiii–Diii show higher magniﬁcations of transfected sides of embryos at E6.5. The white dotted line shows the ventral boundary of the neural tube. At E6.5,WT
(Biii), Q (Ciii) andM (Diii) isoforms showmis-localisation to the axon projections, as opposed to their localisation in the cell bodies but not in axons as seen in (Bi–Di; Bii-Dii) at E4.5. Scale
bar = 100 μm.
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concentrations by western blot showed an increase in levels of over-
expressed protein with higher concentration of plasmid DNA (Figs. 2F,
H). The higher toxicity shown in the current study is thereforemost like-
ly due to an increase in the number of neuroepithelial cells transfected
using higher plasmid concentrations. In order to assess the effects of
over-expressed TDP-43 on endogenous TDP-43, we transfected neurons
in vitrowith EGFP control plasmid and EGFP-tagged TDP-43WT andmu-
tant plasmids, and performed Western blots using anti-TDP43 antibod-
ies. We observed that over-expression of TDP-43 WT or mutants
caused a slight increase in the level of endogenous TDP-43 protein
relative to the EGFP control (Fig. 2G). Taken together, these data demon-
strate that over-expression of wild-type and mutant TDP-43 causes
neurotoxicity in the chick embryo spinal cord, effectswhich are primarily
due to the introduced construct.
Mutant TDP-43 forms nuclear inclusions andmis-localises to the cytoplasm
One of the current hypotheses for the toxicity of TDP-43 is that the
mislocalisation of protein in the cytoplasm, leads to cellular dysfunction
and degeneration. We therefore tested whether the wild-type or mu-
tant forms of TDP-43 showed cellular mislocalisation in vivo. Confocal
microscopical analysis at the cellular level was performed on cryosec-
tions of embryos, in which the spinal cord had been electroporated at
E2.5 and reincubated for 24 h until E3.5 and immunostained as
described above. EGFP-electroporated control embryos showed 100% cy-
toplasmic localisation of EGFP signal as expected (Figs. 3, Ai–Aii).
Embryos transfected with EGFP-taggedWT-TDP-43 showed cytoplasmic
localisation in 12% of cells (Figs. 3Bi, Bii, E). By contrast, embryos
electroporated with EGFP-tagged Q and M TDP-43 showed cytoplasmic
mis-localisation in approximately 33% and 52% of cells respectively
(Figs. 3Ci, Cii, Di, Dii, E). We also observed the presence of intranuclear
inclusions in the embryos electroporated with TDP-43 mutant forms
(Figs. 3Cii, Dii). The cytoplasmic mis-localisation of the Q and Mmutant
proteins was signiﬁcantly higher than in the wild-type (p b 0.05 and
p b 0.01, respectively). This increase in the cytoplasmic mis-localisation
upon electroporation of EGFP-tagged TDP-43 constructs correlates well
with the cellular toxicity shown for the mutant forms (Figs. 1 and 2).
TDP-43 shows enhanced cytoplasmic mis-localisation over time in vivo
In order to determine how the subcellular localisation of TDP-43
changed over developmental time, we electroporated EGFP-tagged con-
structs as above at E2.5 and analysed the embryos at E4.5, E5.5 and E6.5.
Cryosections were immunostained using antibodies against EGFP to vi-
sualise the distribution of TDP-43 protein, andwith antibodies against a
neuroﬁlament-associated antigen (NAA) in order to visualise the entire-
ty of spinal motor axon projections. Motor axon projections extending
via the ventral roots were NAA-positive at E4.5 and E6.5, showing that
the general architecture of axon tracts was preserved (Fig. 4). At all
stages analysed, EGFP control protein was localised to the cell bodies
and axonswhich extended out of the spinal cord and into the periphery
via the ventral roots (Figs. 4Ai–Aiii; data not shown). This reﬂects the
fact that cytoplasmic EGFP is distributed throughout motor axons fol-
lowing electroporation (e.g. Miyake et al., 2008). By contrast, we ob-
served striking changes in the localisation of EGFP-tagged TDP-43
protein over time by immunostaining with anti-GFP antibodies to de-
tect the TDP-43 protein localisation. At E4.5 and E5.5, the expression
of EGFP-tagged WT and mutant TDP-43 was localised to the neuronal
cell bodies (as observed by immunostaining using anti-EGFP antibody),
with EGFP signal visible up to the edge of the spinal cord (Figs. 4Bi, Bii,
Ci, Cii, Di, Dii; data not shown). By contrast, at E6.5, WT, Q and M TDP-
43 protein could be detected in motor axons extending via the ventral
roots some hundreds of microns away from the spinal cord (Figs. 4Biii,
Ciii, Diii; immunostaining for the EGFP tag). Some evidence of apoptosis
among neurons expressing WT and mutant forms of TDP-43 was ob-
served at these stages (data not shown), but the integrity of the motor
column overall was preserved (Fig. 4). This suggests that at least a pro-
portion of motor neurons which express TDP-43 wild-type and mutant
forms can extend axons along normal pathways in vivo, and that a pro-
gressive translocation of TDP-43 into motor axons occurs over time.
TDP-43 leads to down-regulation of neuroﬁlament-associated antigen and
causes premature truncation and de-fasciculation of axons in vivo
In order to test the molecular effects of wild-type and mutant TDP-
43 on the integrity of axon processes, we analysed the expression of
NAA in spinal motor axons expressing TDP-43 constructs as analysed
at E6.5 (96 hour post electroporation). Immunohistochemistry and
confocal imaging showed that there was robust expression of NAA
which was widely distributed along the axons of neurons transfected
with the EGFP control construct (Fig. 5Ai Aii). However, neuroﬁlament-
associated immunoreactivity was greatly reduced in axons which
expressed wild-type or mutant TDP-43 (Figs. 5Bi, Bii, Ci, Cii, Di, Dii),
suggesting that cytoskeletal components were perturbed by mutant
TDP expression. In EGFP-expressing control embryos, motor axons
which extended via the ventral roots remained closely bundled together
in a fascicle — termed ‘fasciculation’. We observed that over-expression
of WT and mutant TDP-43 resulted in debundling or ‘defasciculation’ of
the transfected axons as they extended into the periphery (Figs. 5Aiii–
Diii). As these data suggest an effect on the cytoskeletal integrity and
pathﬁnding of axon projections, we also analysed the entirety of these
axon projections through serial sections at brachial level, where control
EGFP-expressing motor axons were found to project towards the wing
Fig. 5.Axon projection from ventralmotor neurons transfectedwith TDP-43 shows down-
regulation of NAA and premature de-fasciculation. Representative confocal images of sec-
tions of embryos electroporated with EGFP (Ai–Aiii), or TDP-43 isoforms WT (Bi–Biii;
n = 6), Q (Ci–Ciii; n = 6) and M (Di–Diii; n = 6). Panels Ai–Di show immunostaining
of EGFP (green) and NAA (red), whereas panels Aii–Dii show immunostaining of NAA
only. It is evident that upon over-expression of TDP-WT and mutant forms, there is a de-
crease in NAA immunostaining (arrowheads in Bii–Dii). Panels Aiii–Diii represent immu-
nostaining for EGFP, demonstrating premature defasciculation of axon projections
(arrows in Biii–Diii). Asterisks represent the edge of the neural tube. Scale bar = 100 μm.
30 V.B. Tripathi et al. / Neurobiology of Disease 65 (2014) 25–34
buds (Fig. 6A). A comparison of EGFP-transfected control embryos with
wild-type or mutant TDP-43 embryos showed that motor axons were
aberrantly truncated, with the truncation most striking for the TDP-43
Qmutant (Figs. 6A–D). This suggests that over-expression ofWT or mu-
tant TDP-43 protein impaired normal motor neuron outgrowth, causing
axons to depart from their normal routes and to stop short of their target
structures.
TDP-43 causes cytoplasmic aggregation, reduced neurite outgrowth and
neurotoxicity in vitro
In order to further characterise the effects of TDP-43 on motor axon
growth, we transfected the same EGFP-tagged constructs as above into
chick primary spinal motor neurons, After 24–96 h in culture, the cells
were immunostained with antibodies for the Islet-1/2 motor neuron-
speciﬁc marker and anti-GFP (in order to visualise the distribution of
TDP-43). Analysis of control, EGFP-transfected, Islet-1/2-positive
motor neurons after 24 h in culture showed that the EGFP protein was
distributed throughout the cell body and neurites (Figs. 7Ai-iii). At
24 h, EGFP-tagged TDP-WT and mutant forms however were restricted
to the nucleus of Islet-1/2-positive motor neurons and were not ob-
served to mis-localise to neurites or form aggregates, nor did cellular
toxicity occur (Figs. 7 Bi–Biii, Ci–Ciii, Di–Diii). EGFP-transfected cells at
72 and 96 h were viable and healthy and contained EGFP protein
throughout the neurites (Figs. 7Aiv,Av). However, at the same time
points, we observed increased cell death of neurons transfected with
TDP43-WT and mutant forms, reﬂected by cellular fragmentation and
mis-localisation of all TDP-43 isoforms to axons (Figs. 7Biv, Bv, Civ, Cv,
Div, Dv). Approximately 25% of cells showed evidence of disintegration
and cell death. These results suggest the presence of TDP-43 cytoplas-
mic aggregates and a toxic effect of wild-type and mutant TDP-43
which may be progressive over time, with a time-course following
transfection which is similar to that seen in vivo.
To analyse the effects of TDP-43 on cytoskeletal integrity, we per-
formed immunostaining of the transfected cells with anti-NAA to
identify and measure neurites. Observation of immunostained cultures
at 72 and 96 h demonstrated that surviving motor neurons which
expressed wild-type and mutant TDP-43 had shorter neurites than
neurons expressing the EGFP control plasmid (Fig. 8A-D). Quantitation
suggested that the total neurite length per motor neuron expressing
TDP-43 wild-type and mutant constructs was signiﬁcantly reduced
compared to EGFP control-transfected motor neurons (Fig. 8E;
p b 0.05 for EGFP vs WT, Q and M mutants at 72 h and p b 0.01 for
EGFP vsWT, Q and M mutants at 96 h). These data suggest that the ex-
pression of TDP-43 wild-type and mutant isoforms impairs motor axon
outgrowth in vitro, mirroring the reduction in axonal length seen in vivo.
Conclusions/discussion
In this study, we have analysed the role of TDP-43 in an embryonic
chick model system in vivo and in vitro. We have tested the relative ef-
fects of over-expression of wild-type andmutant TDP-43 onmotor neu-
ron viability, axon outgrowth and cytoskeletal integrity. Our results
demonstrate that TDP-43 causes toxicity to spinal motor neurons;
Fig. 6. Axon projections from spinal motor neurons transfected with TDP-43 show aberrant truncation. To left of dotted line are diagrammatic summaries of transverse sections of spinal
cord showing phenotypes observed as labelled. To right of dotted line are representative images of sections of embryos electroporatedwith EGFP (A), or TDP-43 isoformsWT (B; n = 6),Q
(C; n = 6) andM (D; n = 6). It is apparent that there is aberrant truncation of the axon projections upon over-expression ofwild-type ormutant TDP-43 (Ai, Bi, C, Di; boxed region shows
truncated axons). (Aii, Bii, Cii, Dii) Magniﬁed images of the boxed regions showing de-fasciculation. Scale bar = 100 μm.
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the toxic effects of TDP-43 mutant isoforms were more severe than
those of TDP43-WT. In vivo, TDP-43 shows cytoplasmic localisation to
cell bodies 1–2 days after transfection, and progressive transloca-
tion into motor axons after 4 days. Expression of TDP-43 wild-type
and mutant proteins in motor axons is accompanied by a truncation of
axons en route to their peripheral targets and down-regulation of
a neuroﬁlament-associated antigen. In vitro, spinal motor neurons
which express these isoforms show a similar reduction in neurite
length.
TDP43 shows progressive effects in the chick embryo in vivo
Our in vivo ﬁndings conﬁrm and extend previous work demonstrat-
ing neurotoxicity of TDP-43 in the chick spinal cord (Sreedharan et al.,
2008). Based on the proportion of dying cells and those showing cyto-
plasmic mis-localisation of TDP-43 protein, the effects of mutant iso-
forms were more pronounced than that of the wild-type TDP-43. Our
data in conjunction with other published results (Sreedharan et al.,
2008) suggest that the neurotoxic effects of TDP-43 are correlated
Fig. 7. In vitro analysis of the effects of TDP-43. Representative images of chick primary spinal motor neurons transfected with EGFP (A), or TDP-43 isoformsWT (B), Q (C) andM (D). It is
evident that there is cellular toxicity alongwith aggregation of TDP-43. Panels (Ai–Aiii, Bi–Biii, Ci–Ciii, Di–Diii) show cells at 24 hour post transfection; EGFP stained in green and red stain-
ing represents Islet 1/2. This demonstrates that motor neurons are successfully transfected. Panels (Aiv, Biv, Civ, Div) show cells at 72 hour post transfection. Comparison with EGFP-
transfected cells (Aiv) clearly demonstrates cytotoxicity and cytoplasmic aggregation of transfected TDP-43 (WT (Biv), Q (Civ) andM (Div)). Panels (Av, Bv, Cv, Dv) show cells at 96 hour
post transfection. Comparison with EGFP transfected cells (Av) clearly demonstrates cytotoxicity and cytoplasmic aggregation of transfected TDP-43 (WT (Bv), Q (Cv) andM (Dv)). Scale
bar = 100 μm.
Fig. 8. TDP-43 causes a decrease in process length of neurons in vitro. Representative images of chick primary spinal motor neurons transfected with EGFP (A), or TDP-43 isoformsWT (B),
Q (C) andM (D), cells were analysed after 72 and 96 h in culture for total neurite length. Images represent cells after 96 h in culture. Panels Ai–Di show immunostaining of EGFP-tagged
constructs (green); Panels Aii–Dii show immunostaining of NAA (red); Panels Aiii–Diii show merge of EGFP (green) and NAA (red). The images are taken at the same magniﬁcation in
order to demonstrate the decrease in length of neurites in cells transfected with wild-type and mutant TDP-43. (E) Graph demonstrating mean neurite length. Scale bar = 100 μm.
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with cytoplasmic aggregation/mis-localisation, which in turn may dis-
turb aspects of the RNA processing function of TDP-43. Expression of
mutant TDP-43 in rat cortical neurons led to toxicity after several days
in culture, and there was a strong correlation between the cytoplasmic
mis-localisation and neuronal death (Barmada et al., 2010). However,
it remains an open question whether cytoplasmic localisation per se
leads to cell death in our system. For example, in mouse models of
TDP-43-mediated proteinopathy, although ubiquitinated cytoplasmic
aggregates were observed, these did not contain TDP43, suggesting
that disrupted function of TDP43 DNA/RNA binding rather than cyto-
plasmic aggregation per se is responsible for the toxic effects
(Wegorzewska et al., 2009).
In vivo, we also observed a progressive recruitment of TDP-43 pro-
tein to axons over time, accompanied by aberrant truncation and
defasciculation of axon projections. Our in vivo ﬁndings of motor axon
defasciculation are consistent with previous studies in the zebraﬁsh, in
which over-expression of mutant TDP-43, and to a lesser extent WT-
TDP-43, caused ectopic motor axonal branching phenotypes (Kabashi
et al., 2008; Kabashi et al., 2010).
Our in vivo data paralleled our in vitro ﬁndings demonstrating
that there is a decrease in the axonal length 72 and 96 hour post-
transfection of WT and mutant TDP-43 forms. These data correlate
with recent studies, in which mutant TDP-43 was found to inhibit
neurite outgrowth (Duan et al., 2011), and over-expression of wild-
type (WT) and mutant TDP43 causes toxicity in motor neurons
(Fallini et al., 2012; Kabashi et al., 2010).
The cytoskeleton is a target of TDP-43 dysfunction
In addition to the effects on axon growth we document here, we
found that TDP-43 over-expression is associated with a down-
regulation of NAA.Whereaswe did not quantitatively assess NAA levels
in vitro in the presence of TDP43 overexpression, a reduced level of neu-
roﬁlament expression is a likely correlate of the reduction in axon
length which we observed. Our results contribute to a growing body
of evidence suggesting that TDP-43 functions to regulate the cytoskele-
ton, and that loss of this regulation is an important feature of TDP-43
pathology. One mechanism to explain this dysregulation of the cyto-
skeleton is via aberrant processing or trafﬁcking of RNAs which are
normally bound to TDP-43. Studies in which TDP-43 was shown to
be trafﬁcked into motor axons, and to colocalise with several mRNA-
binding proteins are also consistent with this view (Fallini et al.,
2012). Indeed, TDP-43 has been shown to bind directly to the 3′ UTR
of the low molecular weight (68 kDa) neuroﬁlament mRNA (NFL)
stabilising it to prevent degradation (Strong et al., 2007). Conversely,
in ALS the expression of the NFL mRNA is suppressed or preferentially
sequestered to stress granules (Strong et al., 2007; Volkening et al.,
2009). Over-expression of mutant TDP-43 in Drosophila causes severe
motor deﬁcits and structural defects at the neuromuscular junctions
(Feiguin et al., 2009). Alterations in the organization of synaptic micro-
tubules correlate with reduced protein levels in themicrotubule associ-
ated protein futsch/MAP1B (Godena et al., 2011). In TDP-43 transgenic
mice over-expressing TDP-43 A315T or G348Cmutations, it has been
shown that there are perikaryal aggregation and axonal aggregation
of intermediate neuroﬁlaments (Swarup et al., 2011). Additional
cytoskeletal targets of TDP-43 in the chick embryo remain to be
characterised.
To conclude, our data suggest that TDP-43 regulates axon outgrowth
and the integrity of the cytoskeleton, and that dysfunction of TDP-43 con-
tributes to the pathology of ALS. We here demonstrate the advantages of
the chick embryo system, in allowing characterisation over several em-
bryonic stages of the progressive recruitment of TDP-43 wild-type and
mutant protein to motor axons These observations suggest that early
stages of chick developmentmight encapsulate an acutemodel of chang-
es taking place over a longer timescale in mice or in humans.
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